Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Modifications in the tumor microenvironment (TME) play a major role in the establishment, progression, and metastasis of cancer. Matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) is a powerful technique that enables the simultaneous identification and localization of biological compounds within tissues. To detect markers of early TME remodeling in invasive breast cancer, we used MALDI-MSI to compare the molecular profiles of tissues from the breast cancer interface zone, tumor zone, and normal-tissue zone. Using direct-tissue MALDI tandem mass spectrometry (MS/MS), we identified
immunoglobulin heavy constant alpha 2
(
IGHA2
) as a new, zone-specific protein in the breast TME. The zone-specific expression of
IGHA2
was verified by immunoblotting and immunohistochemical analysis.
IGHA2
expression was consistently positive in tumor cells that were metastatic to regional nodes, with intense expression along the cytoplasmic borders. As a factor related to an increased percentage of nodes with tumor metastasis,
IGHA2
expression was upregulated 3.745-fold in cases with an increased number of cancerous nodes (p = 0.0468). Our results provide the first evidence of
IGHA2
as a marker of the early process of TME remodeling in invasive breast cancer. Furthermore,
IGHA2
may be a novel marker for regional
metastases
in the lymph nodes of patients with breast cancer.
...
PMID:In situ identification and localization of IGHA2 in the breast tumor microenvironment by mass spectrometry. 2289 99